New cancer drug ZL-6201 enters early human testing

NCT ID NCT07374848

Recruiting now Disease control Sponsor: Zai Lab (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMAS SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China
Zai Lab Site 02002
RECRUITING

New York, New York, 10065, United States
Zai Lab Site 02003
RECRUITING

Los Angeles, California, 90007, United States
Zai Lab Site 02005
RECRUITING

St Louis, Missouri, 63160, United States
Zai Lab Site 02006
RECRUITING

Fairfax, Virginia, 22031, United States
Zai Lab Site 02026
RECRUITING

Sarasota, Florida, 34232, United States
Zai Lab Site 02030
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.